Tracking azole resistance in Aspergillus from lung samples
Part of Infections clinical trials.
This study looks at Aspergillus fungus samples from people’s lungs to understand why some become resistant to a key treatment (azole medicines). If you’ve had a sample showing Aspergillus in the past few years and live in certain areas of France, you may be able to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You agree to take part in the study
- You are covered by French social security
- You have had a lung sample (such as sputum or fluid) between 2020–2023, or anytime from 2024 onward, that grew Aspergillus fungus
- You live in the Loire Atlantique or Vendée region of France
- You are not under guardianship or legal protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This study is testing a new blood or fluid test that may find drug-resistant fungus in people with a weakened immune system who have a serious lung infection. The results could help doctors choose the right medicine faster.
This study looks at whether repeated PCR tests for a fungus called Aspergillus fumigatus (in blood or lung fluid) can help doctors track how well treatment is working for a serious lung infection called invasive aspergillosis. It is for people who already had a positive PCR test at diagnosis.
This study aims to detect invasive lung aspergillosis earlier by testing samples from your lungs and measuring specific lab markers. It may help doctors start the right antifungal treatment sooner when the infection is suspected.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
Hear when a new Aspergillus Fumigatus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.